pomalidomide-bortezomib-dexamethasone
15 abstracts
Abstract
Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38–directed therapy: MagnetisMM-32.Org: UCHealth Cancer Care and Hematology, Department of Hematology, Yamagata University Hospital,
Abstract
Post-ASCT consolidation with EPD or ERD in patients with high-risk multiple myeloma.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).Org: Princess Margaret Cancer Centre, Ankara University, University Hospital Brno, General Hospital Evangelismos, Athens, Greece, St. Vincent's Hospital Melbourne,
Abstract
Analysis of real-world (RW) pomalidomide (pom) dosing patterns in patients (pts) with multiple myeloma (MM) from the Flatiron database.Org: Myeloma, Waldenstrom’s and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy,
Abstract
Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in.Org: Winship Cancer Center of Emory University, Emory University, Atlanta, GA, USA, Emory University School of Medicine, Biostatistics Shared Resource, Winship Cancer Institute of Emory University,
Abstract
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.Org: University College London Cancer Institute, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Medical College of Wisconsin, Peter MacCallum Cancer Centre, Melbourne, Australia, Hematology Clinic,
Abstract
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).Org: Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, The Wistar Institute, Active Biotech,
Abstract
MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.Org: Centre Hospitalier Universitaire de Nantes, Clinica São Germano, São Paulo, Brazil, Columbia University Medical Center, Sylvester Comprehensive Cancer Center, Miami, FL, Janssen Research & Development,
Abstract
A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health,
Abstract
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study.Org: Cerner Enviza, Pfizer Inc., London, United Kingdom,
Abstract
Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM).Org: Queen Elizabeth II Health Sciences Centre and Dalhousie University, David Geffen School of Medicine at UCLA, Banner MD Anderson Cancer Center, Division of Hematology/Oncology, Columbia University, Clalit Health Services, Ha’Emek Medical Center,
Abstract
Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.Org: Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, University Federico II, Cimitile, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST (IRCCS) s,
Abstract
Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment.Org: Vanderbilt University Medical Center, Hematology Department, Hospital Universitari i Politècnic La Fe, CHU Nantes-Department of Hepato-Gastroenterology, University of North Carolina School of Medicine, University of Wisconsin Health,
Abstract
Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis.Org: Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, Massachusetts General Hospital, Boston, MA, USA, The University of Arizona, Tucson, AZ, Faculty of Health Sciences, Hamilton, ON, Canada,